123 related articles for article (PubMed ID: 11166905)
1. Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine.
Guy B; Pascal N; Françon A; Bonnin A; Gimenez S; Lafay-Vialon E; Trannoy E; Haensler J
Vaccine; 2001 Feb; 19(13-14):1794-805. PubMed ID: 11166905
[TBL] [Abstract][Full Text] [Related]
2. Cationic liposomes as adjuvants for influenza hemagglutinin: more than charge alone.
Barnier Quer C; Elsharkawy A; Romeijn S; Kros A; Jiskoot W
Eur J Pharm Biopharm; 2012 Jun; 81(2):294-302. PubMed ID: 22487055
[TBL] [Abstract][Full Text] [Related]
3. Attachment of class B CpG ODN onto DOTAP/DC-chol liposome in nasal vaccine formulations augments antigen-specific immune responses in mice.
Tada R; Muto S; Iwata T; Hidaka A; Kiyono H; Kunisawa J; Aramaki Y
BMC Res Notes; 2017 Jan; 10(1):68. PubMed ID: 28126014
[TBL] [Abstract][Full Text] [Related]
4. A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice.
Joseph A; Itskovitz-Cooper N; Samira S; Flasterstein O; Eliyahu H; Simberg D; Goldwaser I; Barenholz Y; Kedar E
Vaccine; 2006 May; 24(18):3990-4006. PubMed ID: 16516356
[TBL] [Abstract][Full Text] [Related]
5. Preclinical evaluation of Vaxfectin-adjuvanted Vero cell-derived seasonal split and pandemic whole virus influenza vaccines.
Smith LR; Wodal W; Crowe BA; Kerschbaum A; Bruehl P; Schwendinger MG; Savidis-Dacho H; Sullivan SM; Shlapobersky M; Hartikka J; Rolland A; Barrett PN; Kistner O
Hum Vaccin Immunother; 2013 Jun; 9(6):1333-45. PubMed ID: 23857272
[TBL] [Abstract][Full Text] [Related]
6. Cationic DDA/TDB liposome as a mucosal vaccine adjuvant for uptake by dendritic cells in vitro induces potent humoural immunity.
Qu W; Li N; Yu R; Zuo W; Fu T; Fei W; Hou Y; Liu Y; Yang J
Artif Cells Nanomed Biotechnol; 2018; 46(sup1):852-860. PubMed ID: 29447484
[TBL] [Abstract][Full Text] [Related]
7. Development and characterization of chitosan coated poly-(ɛ-caprolactone) nanoparticulate system for effective immunization against influenza.
Gupta NK; Tomar P; Sharma V; Dixit VK
Vaccine; 2011 Nov; 29(48):9026-37. PubMed ID: 21939718
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity, protective efficacy and mechanism of novel CCS adjuvanted influenza vaccine.
Even-Or O; Samira S; Rochlin E; Balasingam S; Mann AJ; Lambkin-Williams R; Spira J; Goldwaser I; Ellis R; Barenholz Y
Vaccine; 2010 Sep; 28(39):6527-41. PubMed ID: 20412874
[TBL] [Abstract][Full Text] [Related]
9. Mucosal immunization with recombinant influenza hemagglutinin protein and poly gamma-glutamate/chitosan nanoparticles induces protection against highly pathogenic influenza A virus.
Moon HJ; Lee JS; Talactac MR; Chowdhury MY; Kim JH; Park ME; Choi YK; Sung MH; Kim CJ
Vet Microbiol; 2012 Dec; 160(3-4):277-89. PubMed ID: 22763171
[TBL] [Abstract][Full Text] [Related]
10. Intranasal Immunization with DOTAP Cationic Liposomes Combined with DC-Cholesterol Induces Potent Antigen-Specific Mucosal and Systemic Immune Responses in Mice.
Tada R; Hidaka A; Iwase N; Takahashi S; Yamakita Y; Iwata T; Muto S; Sato E; Takayama N; Honjo E; Kiyono H; Kunisawa J; Aramaki Y
PLoS One; 2015; 10(10):e0139785. PubMed ID: 26440657
[TBL] [Abstract][Full Text] [Related]
11. Vaxfectin, a cationic lipid-based adjuvant for protein-based influenza vaccines.
Hartikka J; Bozoukova V; Yang CK; Ye M; Rusalov D; Shlapobersky M; Vilalta A; Wei Q; Rolland A; Smith LR
Vaccine; 2009 Oct; 27(46):6399-403. PubMed ID: 19552895
[TBL] [Abstract][Full Text] [Related]
12. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
de Haan A; Haijema BJ; Voorn P; Meijerhof T; van Roosmalen ML; Leenhouts K
Vaccine; 2012 Jul; 30(32):4884-91. PubMed ID: 22537989
[TBL] [Abstract][Full Text] [Related]
13. Alkyl polyglycoside, a highly promising adjuvant in intranasal split influenza vaccines.
Wu H; Bao Y; Wang X; Zhou D; Wu W
Hum Vaccin Immunother; 2017 Jun; 13(6):1-9. PubMed ID: 28129034
[TBL] [Abstract][Full Text] [Related]
14. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H
J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232
[TBL] [Abstract][Full Text] [Related]
15. Nasal vaccination with pneumococcal surface protein A in combination with cationic liposomes consisting of DOTAP and DC-chol confers antigen-mediated protective immunity against Streptococcus pneumoniae infections in mice.
Tada R; Suzuki H; Takahashi S; Negishi Y; Kiyono H; Kunisawa J; Aramaki Y
Int Immunopharmacol; 2018 Aug; 61():385-393. PubMed ID: 29945026
[TBL] [Abstract][Full Text] [Related]
16. Intranasal hydroxypropyl-β-cyclodextrin-adjuvanted influenza vaccine protects against sub-heterologous virus infection.
Kusakabe T; Ozasa K; Kobari S; Momota M; Kishishita N; Kobiyama K; Kuroda E; Ishii KJ
Vaccine; 2016 Jun; 34(27):3191-3198. PubMed ID: 27160037
[TBL] [Abstract][Full Text] [Related]
17. Intranasal c-di-GMP-adjuvanted plant-derived H5 influenza vaccine induces multifunctional Th1 CD4+ cells and strong mucosal and systemic antibody responses in mice.
Madhun AS; Haaheim LR; Nøstbakken JK; Ebensen T; Chichester J; Yusibov V; Guzman CA; Cox RJ
Vaccine; 2011 Jul; 29(31):4973-82. PubMed ID: 21600260
[TBL] [Abstract][Full Text] [Related]
18. Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection.
Hong SH; Byun YH; Nguyen CT; Kim SY; Seong BL; Park S; Woo GJ; Yoon Y; Koh JT; Fujihashi K; Rhee JH; Lee SE
Vaccine; 2012 Jan; 30(2):466-74. PubMed ID: 22051136
[TBL] [Abstract][Full Text] [Related]
19. Influenza hemagglutinin vaccine with poly(gamma-glutamic acid) nanoparticles enhances the protection against influenza virus infection through both humoral and cell-mediated immunity.
Okamoto S; Yoshii H; Akagi T; Akashi M; Ishikawa T; Okuno Y; Takahashi M; Yamanishi K; Mori Y
Vaccine; 2007 Nov; 25(49):8270-8. PubMed ID: 17977633
[TBL] [Abstract][Full Text] [Related]
20. Intranasal Inactivated Influenza Vaccines: a Reasonable Approach to Improve the Efficacy of Influenza Vaccine?
Tamura S; Ainai A; Suzuki T; Kurata T; Hasegawa H
Jpn J Infect Dis; 2016; 69(3):165-79. PubMed ID: 27212584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
